Cash conversion is highly volatile, with FCF swinging from -$177.0M in 2026Q2 to +$127.5M in 2025Q4, driven by working-capital swings of -$97.3M to +$99.7M, while no dividends or buybacks have been deployed.
Privia Health Group, Inc. (PRVA) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | -47.04M | 163.4M | 109.28M | 80.78M | 47.2M | 55.06M | 38.89M | 24.36M | 5.25M |
| Operating CF Margin % | - | 7.7% | 6.29% | 4.87% | 3.48% | 5.7% | 4.76% | 3.1% | 0.8% |
| Operating CF Growth % | -2299.75% | 49.53% | 35.28% | 71.17% | -14.28% | 41.57% | 59.66% | 364.05% | - |
| Net Income | 28.12M | 22.92M | 14.38M | 23.08M | -12.06M | -190.65M | 30.9M | 7.95M | -4.19M |
| Depreciation & Amortization | 6.64B | 9.91M | 7.27M | 6.53M | 4.57M | 2.46M | 1.83M | 1.43M | 1.07M |
| Stock-Based Compensation | 41.32B | 0 | 0 | 0 | 67.36M | 253.53M | 484K | 207K | 1.94M |
| Deferred Taxes | 8.2M | 10.87M | 8.82M | 7.46M | -7M | -28.41M | -7.83M | 716K | -258K |
| Other Non-Cash Items | -61.41B | 75.42M | 59.34M | 35.05M | 687K | 157K | 134K | 332K | 147K |
| Working Capital Changes | -64.66M | 44.29M | 19.47M | 8.66M | -6.35M | 17.97M | 13.37M | 13.73M | 6.54M |
| Change in Receivables | -87.55M | -36.67M | -19.82M | -96.88M | -72.2M | -14.64M | -21.78M | -6.18M | 320K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -64.47M | 14.82M | 52.85M | 118.36M | 6.85M | 0 | 4.71M | -4.14M | -983K |
| Cash from Investing | -104M | -181.57M | -10.32M | -48.01M | -104K | -32.77M | -380K | -5.71M | -165K |
| Capital Expenditures | -1.2M | -1.2M | -5.02M | -113K | -104K | -547K | -380K | -5.71M | -220K |
| CapEx % of Revenue | 0.05% | 0.06% | 0.29% | 0.01% | 0.01% | 0.06% | 0.05% | 0.73% | 0.03% |
| Acquisitions | -11.52B | -181.72M | -5.3M | -47.89M | 125K | -32.23M | 0 | 0 | 55K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 11.42B | 1.34M | 0 | 0 | -125K | 0 | 0 | 0 | 0 |
| Cash from Financing | -5.83M | 6.7M | 2.68M | 8.74M | -19.68M | 213.66M | -767K | -10.87M | 15.36M |
| Debt Issued (Net) | -2.46M | -2.46M | 0 | 0 | -33.25M | -875K | -875K | -10.87M | 15.25M |
| Equity Issued (Net) | 3.92M | 8.05M | 2.68M | 8.74M | 13.45M | 223.69M | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -7.29M | 1.11M | 0 | 0 | 125K | -9.15M | 108K | 0 | 106K |
| Net Change in Cash | -156.87M | -11.46M | 101.64M | 41.52M | 27.41M | 235.94M | 37.74M | 7.78M | 20.44M |
| Free Cash Flow | -48.24M | 162.2M | 104.26M | 80.67M | 47.09M | 54.51M | 38.51M | 18.65M | 5.03M |
| FCF Margin % | -2.05% | 7.64% | 6% | 4.87% | 3.47% | 5.64% | 4.71% | 2.37% | 0.76% |
| FCF Growth % | -152.53% | 55.57% | 29.24% | 71.31% | -13.61% | 41.55% | 106.5% | 270.83% | - |
| FCF per Share | -0.37 | 1.26 | 0.83 | 0.65 | 0.43 | 0.51 | 0.36 | 0.18 | 0.05 |
| FCF Conversion (FCF/Net Income) | -1.72x | 7.13x | 7.60x | 3.50x | -5.50x | -0.29x | 1.24x | 2.95x | -1.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 713K | 888K | 1.93M | 9.2M | 3.72M |
| Taxes Paid | 0 | 0 | 0 | 0 | 307K | 504K | 381K | 316K | 27K |
Quick answers to the most common questions about buying PRVA stock.
Privia Health Group, Inc. (PRVA) generated $163.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Privia Health Group, Inc. (PRVA) generated $162.2M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Privia Health Group, Inc. (PRVA) spent $1.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Thin margins and EPS volatility
Metrics are mathematically derived from official filings.
Cash Conversion Volatility Signals Timing Distortions
Operating cash flow swung from -$177.1M in 2026Q2 to +$127.5M in 2025Q4, per reported figures, with OCF/NI ranging from -19.6 to 13.9, indicating significant timing effects.
The extreme quarterly swings in operating cash flow relative to net income suggest that working capital changes, not core earnings, are driving cash generation. The negative OCF/NI in 2026Q2 and 2026Q1, despite positive net income, implies that revenue recognition and cash collection are misaligned, possibly due to the timing of shared savings true-ups. Investors should monitor whether this volatility reflects structural seasonality or a deterioration in cash conversion quality.
Free Cash Flow Trajectory Remains Lumpy
Free cash flow ranged from -$177.0M in 2026Q2 to +$127.5M in 2025Q4, per financial statements, with FCF margins swinging from -28.0% to 23.6%, highlighting the lumpy nature of VBC settlements.
The FCF trajectory is highly erratic, with negative FCF in the first half of 2026 and 2025, but strong positive FCF in the fourth quarters. This pattern suggests that cash inflows from value-based care arrangements are concentrated in Q4, while Q1 and Q2 experience outflows due to working capital needs. The reported net income remains positive but does not correlate with FCF, indicating that accruals and timing differences are significant. The raised guidance for 2026 implies management expects a back-half acceleration, but the cash flow data suggests this is not yet visible.
Working Capital Swings Dominate Cash Flow
Working capital changes ranged from -$97.3M in 2026Q2 to +$99.7M in 2025Q4, per reported data, driving the majority of operating cash flow volatility and obscuring underlying profitability.
The working capital line is the primary driver of the extreme quarterly cash flow swings, with negative changes in Q1 and Q2 of each year and positive changes in Q4. This pattern likely reflects the timing of premium collections and shared savings settlements, which are recognized on an accrual basis but collected later. The magnitude of these swings (over $100M) relative to net income (under $10M) suggests that the company's cash conversion is heavily dependent on the timing of receivables and payables, not on operational performance. Investors should focus on the annualized cash flow rather than quarterly figures to assess the underlying trend.
Capital Deployment Minimal Amid Cash Accumulation
No dividends or buybacks were reported in the last ten quarters, per SEC filings, while cash reserves stood at $479M, indicating a conservative capital allocation strategy focused on organic growth.
The company has not returned capital to shareholders through dividends or buybacks, and acquisition activity has been minimal, with net cash outflows for acquisitions only in certain quarters. This conservative approach, combined with a fortress balance sheet (nearly zero debt), suggests management is prioritizing liquidity and organic expansion. However, the lack of capital deployment may indicate limited attractive investment opportunities or a desire to maintain a cash buffer for potential strategic moves. The high cash position relative to market cap could be a source of value if deployed effectively, but it also implies a low return on excess cash.
Cumulative Earnings Outpace Cash Generation
Over the last ten quarters, cumulative net income was approximately $49.5M, while cumulative operating cash flow was only $45.2M, per reported data, indicating a slight divergence that may reflect timing differences.
The cumulative gap between net income and operating cash flow is relatively small, suggesting that over time, earnings are being converted to cash. However, the quarterly volatility is extreme, with cash flow often negative in the first half of the year and positive in the fourth quarter. This pattern may indicate that the company's business model inherently generates cash late in the year, possibly due to the timing of shared savings distributions. The divergence is not alarming, but it warrants monitoring to ensure that the timing of cash flows does not mask a deterioration in earnings quality.
Cash Flow Statement Obscures True Economics
Stock-based compensation of $41.3B in 2026Q2, as reported, appears to be a data error, but even normal SBC levels can mask cash burn in a low-margin business, per financial statements.
The reported SBC figure of $41.3B in 2026Q2 is clearly an outlier and likely a data error, but it highlights the importance of scrutinizing non-cash charges. In a business with thin gross margins (9.9% TTM), SBC can significantly distort reported profitability relative to cash generation. Additionally, the company reports revenue on both gross and net bases, which can obscure the true 'care margin' that drives cash flow. Investors should adjust for SBC and focus on cash-based metrics like 'Platform Contribution' to assess the underlying cash-generating ability of the business.